Toggle Menu Toggle Search

To ensure that new discoveries deliver patient benefits, we work with industry partners through commercial partnerships, industry-sponsored research and university spin-out companies. We have expertise in navigating regulatory pathways, particularly the introduction of new areas of technology and in clinical trials.

We have a number of highly-productive relationships with small and large companies, particularly in the areas of diagnostic development, vaccines, and clinical trials.

The institute has an impressive record of generating spin-out companies, creating commercial development opportunities for our research, ranging from fundamental scientific discoveries to close-to-clinic applications. 

New Technologies for Point-of-Care Diagnostics

Professor Sanjeev Krishna and Dr Henry Staines are working with Newcastle-based industrial partners - QuantuMDx- to implement new technologies that use cheap, rapid and disposal cartridges for point-of-care diagnostics of HPV.

Transformative Diagnostics for Tuberculosis

Professor Philip Butcher and his team are working with the UK Biotech company QuantuMDx Ltd to develop much needed novel technologies for improving the diagnosis of tuberculosis (TB).

Molecular Surveillance of Vaccine Impact

Dr Jason Hinds and BμG@S Bioscience are harnessing the power of microbial genomics to assess the impact of international vaccine roll-out initiatives.

Rescuing Antibiotics

Dr Tim Bull and Dr Kai Hilpert are developing a novel method to stimulate growth of mycobacteria, with important implications for human and veterinary medicine.

Antibiotic Rejuvenation

Professor Anthony Coates and Dr Yanmin Hu have adopted an innovative approach to rejuvenate antibiotics rendered ineffective by resistance.

 

Find a profileSearch by A-Z